Ligand ID: ASW


Drugbank ID:
DB00276
(Amsacrine)


Indication:
For treatment of acute myeloid leukaemia.

Get human targets for ASW in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ASW' AND SARS-RELATED PROTEINS ONLY

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 6
PRO B 108
GLY B 174
ALA B 129
GLN B 192
1.36A18.02
None
None
None
AZP  B 307 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		5 / 7
ILE B 205
PRO B 307
GLY B 279
ALA B 232
GLN B 320
1.78A11.93
None
None
None
GOL  B1004 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		4 / 6
PRO D 307
GLY D 230
ALA D 311
GLN D 244
1.48A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		4 / 7
ILE E 125
PRO E 126
ALA E 157
GLN E 163
1.10A13.93
None
GOL  E2001 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO B 108
GLY B 174
ALA B 129
GLN B 192
1.31A17.87
None
None
None
ENB  B1145 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2dd8 IGG HEAVY CHAIN
IGG LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  49
ALA H  78
GLN L  89
1.36A14.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		5 / 7
ILE C  24
PRO C 126
GLY C  98
ALA C  51
GLN C 139
1.75A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		4 / 6
PRO A 126
GLY A 131
ALA A  51
GLN B 120
1.26A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		4 / 6
PRO A 310
GLY A 336
ALA A 314
GLN A 282
1.53A9.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2jzf REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
PRO A 519
ARG A 544
GLY A 577
ALA A 538
1.48A12.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2ofz NUCLEOCAPSID PROTEIN
(SARS-COV
Tor2)		4 / 6
PRO A 118
ARG A  89
ALA A  51
GLN A  59
1.50A10.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 6
PRO A  67
GLY A  76
ALA A  80
GLN A 187
1.49A18.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.34A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 6
PRO A  67
GLY A  76
ALA A  80
GLN A 187
1.33A18.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 6
ARG B 204
GLY B 205
ALA B 191
GLN B 221
1.45A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.30A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO D 108
GLY D 174
ALA D 129
GLN D 192
1.21A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.26A17.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
ARG A 219
GLY A 221
GLU A 222
GLN A 255
1.19A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 6
ARG A 219
GLY A 221
GLU A 222
GLN A 255
1.20A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5f22 NSP8
(SARSr-CoV)		4 / 7
ILE B 125
PRO B 126
ALA B 157
GLN B 163
1.19A10.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
ARG B 139
GLY D 257
ALA B 142
GLN D 123
1.53A17.64
SO4  B 402 (-2.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x4r S PROTEIN
(MERS-CoV)		4 / 7
ILE A  48
PRO A  76
GLY A 255
GLN A  60
1.42A17.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
ILE A 995
GLY A 751
ALA A 998
GLN C 939
1.09A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
PRO A 697
GLY B 867
ALA B 874
GLN B1018
1.40A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
PRO C  76
GLY C  73
ALA C 336
GLN A 819
1.48A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x5c S PROTEIN
(MERS-CoV)		4 / 7
ILE B1165
PRO B1167
GLY B 984
ALA C 962
1.11A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ILE C 696
PRO C 697
GLY B 873
GLN B 769
0.89A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PRO B1061
GLY B1075
ALA A 881
GLN B1088
1.36A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PRO C 697
GLY A 867
ALA A 874
GLN A1018
1.55A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE C 696
PRO C 697
GLY A 873
GLN A 769
1.14A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PRO C 697
GLY A 867
ALA A 874
GLN A1018
1.41A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE B 696
PRO B 697
GLY C 873
GLN C 769
0.94A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m1d ACE2
(Homo
sapiens)		4 / 6
ARG B 393
GLY B 395
ALA B 386
GLN B  98
1.51A22.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ILE B 696
PRO B 697
GLY A 873
GLN A 769
1.15A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PRO C 697
GLY B 867
ALA B 874
GLN B1018
1.29A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6nur NSP8
(SARSr-CoV)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.17A13.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  49
ALA H  78
GLN L  89
1.56A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  95
ALA H  78
GLN H   1
1.69A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
PRO H  52
GLY H  94
ALA H  78
GLN H   1
1.14A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 7
ILE H  69
GLY H 106
ALA H  78
GLN L  38
1.28A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
ILE H  69
GLY H 106
ALA H  78
GLN H  39
1.68A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  94
ALA H  78
GLN H   1
1.16A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
ILE H  51
GLY H 104
ALA H  78
GLN H   1
1.70A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE B  70
GLY B 112
ALA B  79
GLN C  44
1.30A
None
MLI  B 304 ( 4.8A)
None
1PE  C 301 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.26A
None
None
None
1PE  L1603 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  99
ALA H  79
GLN H   1
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  49
ALA B  79
GLN C  95
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  98
ALA B  79
GLN B   1
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  99
ALA B  79
GLN B   1
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO B 153
GLY B  42
ALA B 172
GLN C  44
1.72A
None
1PE  C 301 (-4.6A)
None
1PE  C 301 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO L  50
GLY H 112
ALA H  97
GLN B   6
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO C  50
GLY B 112
ALA B  97
GLN H   6
1.63A
None
MLI  B 304 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE L 112
ALA L  12
GLU L 111
GLN L  44
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  49
ALA B  79
GLN C  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  99
ALA B  79
GLN B   1
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  98
ALA B  79
GLN B   1
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  99
ALA H  79
GLN H   1
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
ILE B  70
GLY B 112
ALA B  79
GLN C  44
1.26A
None